Skip to main content
. 2021 Jul 1;9:20. doi: 10.1186/s40345-021-00226-4

Table 1.

Demographic and clinical characteristics of trial participants

ThrIVe-B (n = 22) Treatment as usual (n = 21) Total (N = 43)
Gender; n (%)
 Female 14 (64) 9 (43) 23 (53)
 Male 8 (36) 12 (57) 20 (47)
Age in years
 Mean (SD) 43.6 (13.0) 49.3 (14.5) 46.4 (13.9)
 Median [min, max] 43 [20, 68] 51 [24, 75] 44 [20, 75]
Ethnic group; n (%)
 White 22 (100) 20 (95) 42 (98)
 Asian 0 (0) 1 (5) 1 (2)
Prescribed medication for
 Bipolar disorder; n (%) 19 (86) 19 (90) 38 (88)
 Mood stabiliser 14 (63) 12 (57) 26 (61)
 Antipsychotic 10 (46) 14 (67) 24 (56)
 Antidepressant 7 (32) 8 (38) 15 (35)
Site; n (%)
 Devon 17 (77) 17 (81) 34 (79)
 Cumbria 5 (23) 4 (19) 9 (21)
In ongoing secondary care; n (%)
 Yes 2 (9) 4 (19) 6 (14)
 No 20 (91) 17 (81) 37 (86)
Age of depression onseta; mean (SD), n; median [min, max]

19.4 (12.6), 19

16 [6, 58]

18.7 (8.4), 20

18 [6, 44]

19.1 (10.5), 39

18 [6, 58]

Age of mania onset; mean (SD), n; median [min, max]

21.1 (7.9), 15

20 [10, 35]

16.5 (5.7), 17

18 [6, 25]

18.7 (7.1), 32

18 [6, 35]

Bipolar I disorder; n (%) 19 (86) 18 (86) 37 (86)
Bipolar II disorder; n (%) 3 (14) 3 (14) 6 (14)

aMinimum age set to 6 years